JP2023544300A - バリアントｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ ｌｕｋａ及びｌｕｋｂポリペプチド並びにワクチン組成物 - Google Patents

バリアントｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ ｌｕｋａ及びｌｕｋｂポリペプチド並びにワクチン組成物 Download PDF

Info

Publication number
JP2023544300A
JP2023544300A JP2023519355A JP2023519355A JP2023544300A JP 2023544300 A JP2023544300 A JP 2023544300A JP 2023519355 A JP2023519355 A JP 2023519355A JP 2023519355 A JP2023519355 A JP 2023519355A JP 2023544300 A JP2023544300 A JP 2023544300A
Authority
JP
Japan
Prior art keywords
amino acid
seq
variant
luka
lukb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023519355A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023544300A5 (https=
Inventor
モロウ，ブライアン
コンスタンチノフ，セルゲイ
フールトセン，ジェローン
ルオ，ジンクアン
ソマニ，サンディープ
ティー． バックレー，ピーター
ジェイ． トレス，ビクター
Original Assignee
ヤンセン ファーマシューティカルズ，インコーポレーテッド
ニューヨーク ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカルズ，インコーポレーテッド, ニューヨーク ユニバーシティ filed Critical ヤンセン ファーマシューティカルズ，インコーポレーテッド
Publication of JP2023544300A publication Critical patent/JP2023544300A/ja
Publication of JP2023544300A5 publication Critical patent/JP2023544300A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023519355A 2020-09-28 2021-09-28 バリアントｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ ｌｕｋａ及びｌｕｋｂポリペプチド並びにワクチン組成物 Pending JP2023544300A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063084273P 2020-09-28 2020-09-28
US63/084,273 2020-09-28
PCT/US2021/052418 WO2022067255A2 (en) 2020-09-28 2021-09-28 Variant staphylococcus aureus luka and lukb polypeptides and vaccine compositions

Publications (2)

Publication Number Publication Date
JP2023544300A true JP2023544300A (ja) 2023-10-23
JP2023544300A5 JP2023544300A5 (https=) 2024-10-07

Family

ID=80846955

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023519355A Pending JP2023544300A (ja) 2020-09-28 2021-09-28 バリアントｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ ｌｕｋａ及びｌｕｋｂポリペプチド並びにワクチン組成物

Country Status (15)

Country Link
US (1) US20240050546A1 (https=)
EP (1) EP4216982A4 (https=)
JP (1) JP2023544300A (https=)
KR (1) KR20230091911A (https=)
CN (1) CN116670158A (https=)
AR (1) AR123635A1 (https=)
AU (1) AU2021350860A1 (https=)
CA (1) CA3195895A1 (https=)
CL (1) CL2023000884A1 (https=)
CO (1) CO2023004198A2 (https=)
IL (1) IL301406A (https=)
JO (1) JOP20230065A1 (https=)
MX (1) MX2023003581A (https=)
NZ (1) NZ798451A (https=)
WO (1) WO2022067255A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024512751A (ja) * 2021-04-02 2024-03-19 ヤンセン ファーマシューティカルズ，インコーポレーテッド Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓワクチン組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018232014A1 (en) * 2017-06-13 2018-12-20 Integrated Biotherapeutics, Inc. Immunogenic compositions comprising staphylococcus aureus leukocidin luka and lukb derived polypeptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340522C (en) * 1987-03-10 1999-05-04 Heinz Dobeli Fusion proteins containing neighbouring histidines for improved purification
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
EP4015523A1 (en) * 2010-05-05 2022-06-22 New York University Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
RU2016110800A (ru) * 2013-09-25 2017-10-30 Пронутриа Биосайенсис, Инк. Составы и композиции для поддержания и увеличения мышечной массы, силы и результативности, и способы их производства и использования
EP3464349A4 (en) * 2016-05-23 2020-08-26 New York University COMPOSITIONS AND METHODS ASSOCIATED WITH ANTIBODIES TARGETING STAPHYLOCCAL LEUCOTOXINS
CA3215751A1 (en) * 2021-04-02 2022-10-06 Janssen Pharmaceuticals, Inc. Staphylococcus aureus vaccine compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018232014A1 (en) * 2017-06-13 2018-12-20 Integrated Biotherapeutics, Inc. Immunogenic compositions comprising staphylococcus aureus leukocidin luka and lukb derived polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DUMONT, ASHLEY L. ET AL., INFECTION AND IMMUNITY, vol. 82, no. 3, JPN6025041211, 2014, pages 1268 - 1276, ISSN: 0005703140 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024512751A (ja) * 2021-04-02 2024-03-19 ヤンセン ファーマシューティカルズ，インコーポレーテッド Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓワクチン組成物

Also Published As

Publication number Publication date
US20240050546A1 (en) 2024-02-15
CL2023000884A1 (es) 2023-09-29
IL301406A (en) 2023-05-01
AR123635A1 (es) 2022-12-28
EP4216982A4 (en) 2025-03-19
WO2022067255A2 (en) 2022-03-31
CN116670158A (zh) 2023-08-29
JOP20230065A1 (ar) 2023-03-28
CA3195895A1 (en) 2022-03-31
AU2021350860A1 (en) 2023-05-04
EP4216982A2 (en) 2023-08-02
KR20230091911A (ko) 2023-06-23
CO2023004198A2 (es) 2023-07-31
MX2023003581A (es) 2023-06-21
WO2022067255A3 (en) 2022-04-28
NZ798451A (en) 2024-11-29

Similar Documents

Publication Publication Date Title
HUE033342T2 (en) Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof
CN105120892B (zh) 包含艰难梭菌cdtb和/或cdta蛋白的元件的免疫原性组合物
KR102239207B1 (ko) 장내 병원균에 대한 면역 반응을 증진시키는 조성물 및 방법
WO2001045639A2 (en) Methods for protecting against lethal infection with bacillus anthracis
CN105085684B (zh) Pcsk9靶向重组疫苗设计及其应用
JP2023025066A (ja) ワクチン構築物およびブドウ球菌感染症に対するその使用
US20240115688A1 (en) Novel Antigens
JP2015505831A5 (https=)
JP2012532626A (ja) 無毒化されたＥｓｃｈｅｒｉｃｈｉａｃｏｌｉ免疫原
SG176220A1 (en) Casb7439 constructs
JP2023544300A (ja) バリアントｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ ｌｕｋａ及びｌｕｋｂポリペプチド並びにワクチン組成物
US20250281591A1 (en) Staphylococcus aureus vaccine compositions
CN117355328A (zh) 金黄色葡萄球菌疫苗组合物
JP2022550884A (ja) スタフィロコッカス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）ペプチドおよび使用方法
EA049373B1 (ru) Варианты полипептидов luka и lukb staphylococcus aureus и вакцинные композиции
TW202313660A (zh) 變異的金黃色葡萄球菌ＬｕｋＡ和ＬｕｋＢ多肽和疫苗組合物
JP2024529044A (ja) レプトスピラ病毒性調節タンパク質とその使用
WO2016112065A1 (en) Immunogenic composition comprising engineered alpha-hemolysin oligopeptides
US20220332770A1 (en) High-Density Flagellin-Displaying Virus-Like Particle As Vaccine Carrier

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260331